FY2027 Earnings Estimate for BPMC Issued By Zacks Research

Blueprint Medicines Co. (NASDAQ:BPMC) – Investment analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for Blueprint Medicines in a research note issued on Wednesday, March 5th. Zacks Research analyst A. Chakraborty expects that the biotechnology company will post earnings of $3.20 per share for the year. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($1.28) per share.

A number of other equities research analysts have also recently weighed in on the company. Stephens restated an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. Wedbush reiterated an “outperform” rating and set a $128.00 price objective on shares of Blueprint Medicines in a report on Friday, February 28th. HC Wainwright reissued a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research report on Friday, February 14th. Needham & Company LLC reissued a “buy” rating and issued a $133.00 price objective on shares of Blueprint Medicines in a research report on Thursday, February 13th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Blueprint Medicines currently has an average rating of “Moderate Buy” and an average target price of $123.83.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC opened at $89.92 on Thursday. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a 50-day moving average price of $99.50 and a 200 day moving average price of $94.34. Blueprint Medicines has a 52 week low of $80.68 and a 52 week high of $121.90. The company has a market cap of $5.75 billion, a P/E ratio of -83.26 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%.

Insider Activity at Blueprint Medicines

In related news, Director Jeffrey W. Albers sold 15,161 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the sale, the director now owns 152,396 shares of the company’s stock, valued at approximately $16,691,933.88. This trade represents a 9.05 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Kate Haviland sold 1,446 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total value of $159,407.04. Following the transaction, the chief executive officer now owns 149,378 shares of the company’s stock, valued at approximately $16,467,430.72. The trade was a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,427 shares of company stock valued at $4,837,801 in the last quarter. Insiders own 4.21% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Hedge funds have recently added to or reduced their stakes in the stock. Quarry LP acquired a new stake in shares of Blueprint Medicines in the 3rd quarter worth about $32,000. R Squared Ltd acquired a new stake in shares of Blueprint Medicines in the fourth quarter valued at approximately $51,000. Covestor Ltd increased its stake in shares of Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 403 shares during the period. Headlands Technologies LLC bought a new stake in shares of Blueprint Medicines during the fourth quarter valued at approximately $65,000. Finally, Thematics Asset Management acquired a new position in shares of Blueprint Medicines during the fourth quarter worth approximately $72,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.